Vaccinogen, a cancer vaccine company, has promoted Peter Morsing to the position of Chief Operating Officer (COO). He was previously Vaccinogen's Global Head of Business Development & Strategy and is one of five PhD's to have joined the senior ranks of Vaccinogen in the last 13 months.
As COO, Dr Morsing will oversee Vaccinogen's clinical, logistical, manufacturing and business development activities, as well as manage the company's Ireland Research Centre in Dublin. Importantly, he will be responsible for managing Vaccinogen's ACTIVE Phase IIIb OncoVAX clinical trial, its human antibody programme (HuMabs), and the integration of DiCAST, the high throughput, single-cell screening analysis system recently acquired from Dublin City University.
Since joining Vaccinogen in January, Dr Morsing has led internal and external efforts to build value behind Vaccinogen's assets while targeting opportunities to enhance the company's growth potential. Among his accomplishments, Dr Morsing was instrumental in pursuing and securing the option agreement for DiCAST and establishing the company's Ireland Research Centre.
Dr Morsing brings almost 20 years of pharmaceutical and business development experience to the company.
Previously, he held roles of increasing responsibility with AstraZeneca, where he was most recently Search and Evaluation Director and responsible for the identification and evaluation of novel therapeutic approaches to treat cardiovascular and metabolic diseases. He was AstraZeneca's Licensing Director, Strategic Partnering and Business Development, leading global teams in the evaluation of external therapeutic licensing opportunities specialising in diabetes and obesity.
Prior to these positions, Dr Morsing was Portfolio Manager for the Second Swedish National Pension Fund where he was responsible for evaluating and managing investments in the pharmaceutical and biotechnology sectors.
